The most common causes of chronic cough include gastroesophageal reflux disease (GERD), asthma, and postnasal drip (also ...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

Adults with refractory chronic cough who received twice-daily camlipixant had decreases in cough frequency and better scores ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two ...

GSK expects to launch its RCC drug commercially in 2026. Another company that was once ahead in the RCC drug race was Merck MRK, whose chronic cough drug, gefapixant, received two complete response ...

Trevi is also conducting the phase IIb CORAL study, which is evaluating the drug in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Data from this study is expected in the first ...